VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases

American Journal of Clinical Pathology

Volumn 143, Issue 3, 2015, Pages 437-444

  Lee, Sang Ryung ^a   Yim, Hyunee ^a   Han, Jae Ho ^a   Lee, Kyi Beom ^a   Lee, Jeonghun ^a   Soh, Euy Young ^a   Kim, Dae Jung ^a   Chung, Yoon Sok ^a   Jeong, Seon Yong ^a   Sheen, Seung Soo ^a   Park, So Hyun ^a   Kim, Jang Hee ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

BRAF mutation; Fine needle aspiration biopsy; Immunocytochemistry; Liquid based cytology; Thyroid gland

Indexed keywords

ANTIBODY; MUTANT PROTEIN; UNCLASSIFIED DRUG; VE1 ANTIBODY; B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CYTOLOGY; DIAGNOSTIC ACCURACY; FINE NEEDLE ASPIRATION BIOPSY; FINE NEEDLE ASPIRATION CYTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; THYROID ADENOMA; THYROID GLAND; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; ADULT; ANIMAL; DIAGNOSTIC USE; EVALUATION STUDY; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE;

EID: 84928432015     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPOBI5CUZIBMO1     Document Type: Article

References (24)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705-715.
3. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96:2016-2026.
4. Chang H, Lee H, Yoon SO, et al. BRAF (V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol. 2012;43:89-95.
5. Lee ST, Kim SW, Ki CS, et al. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab. 2012;97:2299-2306.
6. Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci. 2013;28:534-541.
7. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38-46.
8. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013;310:535.
9. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493-1501.
10. Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310-317.
11. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118:1764-1773.
12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
13. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012;91:274-286.
14. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF 600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65:660-666.
15. Kang SH, Pyo JY, Yang SW, et al. Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. Am J Clin Pathol. 2013;139:759-764.
16. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
17. Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab. 2013;98:E1414-E1421.
18. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
19. Zimmermann AK, Camenisch U, Rechsteiner MP, et al. Value of immunohistochemistry in the detection of BRAF mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 2014;122:48-58.
20. Lee ST, Kim JY, Kown MJ, et al. Mutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs. J Mol Diagn. 2011;13:657-668.
21. Routhier CA, Mochel MC, Lynch K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013;44:2563-2570.
22. Rossi ED, Martini M, Capodimonti S, et al. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas. Cancer Cytopathol. 2014;122:527-535.
23. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369.
24. Kim YH, Choi SE, Yoon SO, et al. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Hum Pathol. 2014;45:1483-1488.